BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival

Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy arising mostly at end-stage refractory multiple myeloma and consequently presenting limited therapeutic options. We analyzed 13 sPCL for their sensitivity to BH3 mimetics targeting either BCL2 (venetoclax) or B...

Descripción completa

Detalles Bibliográficos
Autores principales: Champion, Ophélie, Soler, Alana, Maïga, Sophie, Bellanger, Céline, Pellat-Deceunynck, Catherine, Talbot, Alexis, Touzeau, Cyrille, Amiot, Martine, Gomez-Bougie, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393035/
https://www.ncbi.nlm.nih.gov/pubmed/37534243
http://dx.doi.org/10.3389/fonc.2023.1196005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393035/
https://www.ncbi.nlm.nih.gov/pubmed/37534243
http://dx.doi.org/10.3389/fonc.2023.1196005

Ejemplares similares